RP1 oncolytic immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RP1 oncolytic immunotherapy, covering 2025-06-11 to 2025-06-11. Get the full timeline:
Most recent: Clinical Trial Update: "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer [Phase 1, Phase 2]